<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157689</url>
  </required_header>
  <id_info>
    <org_study_id>AL-eff 2010</org_study_id>
    <nct_id>NCT01157689</nct_id>
  </id_info>
  <brief_title>Artemether-Lumefantrine Effectiveness in Guinea-Bissau</brief_title>
  <official_title>The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum at the Bandim Health Centre</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bandim Health Project</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bandim Health Project</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The routine treatment of children with antimalarials will be monitored. Children with a&#xD;
      positive malaria film and/or a positive rapid diagnostic test (RDT) will be included in a&#xD;
      follow-up study. The genetic basis of the parasites for developing resistance will be&#xD;
      examined. In case of reappearance of parasites the child will be re-treated following the&#xD;
      guidelines of the national malaria programme.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children from the Bandim area in Bissau who are seeking medical advice and who are&#xD;
      recommended treatment for malaria in accordance with the current routines will be included as&#xD;
      follows:&#xD;
&#xD;
      All children getting the clinical diagnosis of malaria will be registered and basic&#xD;
      information collected. Of theses, children fulfilling the inclusion criteria will be included&#xD;
      in a follow-up study.&#xD;
&#xD;
      The children included in the follow-up part of the study will be visited on day 7, day 14,&#xD;
      day 21, day 28, day 35 and day 42. At each visit the condition of the child will be&#xD;
      evaluated, a questionnaire will be filled in and a malaria film and approximately 100 µl&#xD;
      blood on filter-paper (for PCR analysis in case of re-parasitaemia) will be taken.&#xD;
      Furthermore, on day seven 100 μl blood on filter-paper will be taken for drug-analysis.&#xD;
&#xD;
      Children with parasitaemia detected by only one of the following methods will be excluded&#xD;
      from the final analyses of the effectiveness: 1) malaria film, 2) RDT, and 3) PCR.&#xD;
&#xD;
      If the parents do not ensure that the children get the correct medication resulting in a high&#xD;
      rate of recrudescence and/or a low drug-concentration on day seven the policy of the National&#xD;
      Malaria Programme should be re-evaluated. If the health staff do not follow the guidelines of&#xD;
      the National Malaria Programme the reasons why should be elucidated in order to ensure a&#xD;
      better adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACPR day 42</measure>
    <time_frame>day 42</time_frame>
    <description>Malaria slides will be examined weekly during follow-up until day 42. The adequate clinical and parasitological cure rate will to calculated for day 42.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACPR day 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>During follow-up for 42 days</time_frame>
    <description>All possible side effects will be recorded during the 42 day long follow-up.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Coartem, chloroquine, quinine</arm_group_label>
    <description>All children with a positive malaria test will included. Results will be subanalysed acording to treatment given by routine health staff.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Capillary blood samples for drug concentration analysis and for PCR for identifying the&#xD;
      malaria parasites&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children diagnosed as having malaria at Bandim Health Center in Bissau. Of these all&#xD;
        children with a positive malaria film and/or a positive rapid diagnostic test will be&#xD;
        included in an observational follow-up study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prescribed an anti-malarial at the Bandim Health Centre&#xD;
&#xD;
          -  Having P. falciparum parasites in a thick film and/or a positive RDT&#xD;
&#xD;
          -  The Bandim address is known (to enable follow up).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children where the parents do not accept to participate in the study.&#xD;
&#xD;
          -  Signs of severe malaria such as convulsion or severe anemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bandim Health Project</name>
      <address>
        <city>Bissau</city>
        <state>Bissau Codex</state>
        <zip>1004</zip>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 6, 2010</study_first_submitted>
  <study_first_submitted_qc>July 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2010</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>children</keyword>
  <keyword>Guinea-Bissau</keyword>
  <keyword>artemether</keyword>
  <keyword>lumefantrine</keyword>
  <keyword>effectiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

